These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23561653)

  • 1. Pharmacotherapies for treating opioid use disorder.
    Nguyen TA; Hahn JH; Strakowski SM
    CNS Spectr; 2013 Dec; 18(6):289-95. PubMed ID: 23561653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
    Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
    Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual dilemma-should naltrexone be used in the treatment of opioid-dependent pregnant women?
    Stitzer ML
    Addiction; 2013 Feb; 108(2):249-50. PubMed ID: 23331877
    [No Abstract]   [Full Text] [Related]  

  • 4. Challenges and Opportunities for the Use of Medications to Treat Opioid Addiction in the United States and Other Nations of the World.
    Parrino MW; Maremmani AG; Samuels PN; Maremmani I
    J Addict Dis; 2015; 34(2-3):255-62. PubMed ID: 26110357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The SOMATICS collaborative: Introduction to a National Institute on Drug Abuse cooperative study of pharmacotherapy for opioid treatment in criminal justice settings.
    Chandler RK; Finger MS; Farabee D; Schwartz RP; Condon T; Dunlap LJ; Zarkin GA; McCollister K; McDonald RD; Laska E; Bennett D; Kelly SM; Hillhouse M; Mitchell SG; O'Grady KE; Lee JD
    Contemp Clin Trials; 2016 May; 48():166-72. PubMed ID: 27180088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and current clinical practices of opioid treatment programs in the United States.
    Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
    Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid Use Disorders.
    Sharma B; Bruner A; Barnett G; Fishman M
    Child Adolesc Psychiatr Clin N Am; 2016 Jul; 25(3):473-87. PubMed ID: 27338968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The science and practice of medication-assisted treatments for opioid dependence.
    Pecoraro A; Ma M; Woody GE
    Subst Use Misuse; 2012; 47(8-9):1026-40. PubMed ID: 22676570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapeutic management of co-morbid alcohol and opioid use.
    Hood LE; Leyrer-Jackson JM; Olive MF
    Expert Opin Pharmacother; 2020 May; 21(7):823-839. PubMed ID: 32103695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and emerging pharmacotherapies for opioid dependence treatments in adults: a comprehensive update.
    Leyrer-Jackson JM; Acuña AM; Olive MF
    Expert Opin Pharmacother; 2022 Nov; 23(16):1819-1830. PubMed ID: 36278879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use and misuse of opioid replacement therapies: a Queensland study.
    Smirnov A; Kemp R
    Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using buprenorphine to treat patients with opioid use disorder.
    Radi JK; Fogarty KJ; Lagerwey MD
    JAAPA; 2019 Oct; 32(10):30-35. PubMed ID: 31513035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date.
    Chalhoub RM; Kalivas PW
    Drugs; 2020 Oct; 80(15):1509-1524. PubMed ID: 32776315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-acting naltrexone--a new way out of opiate addiction?].
    Stavseth LS; Kunøe N; Tanum L
    Tidsskr Nor Laegeforen; 2013 Nov; 133(21):2231-2. PubMed ID: 24226324
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of opioid use disorder in primary care.
    Buresh M; Stern R; Rastegar D
    BMJ; 2021 May; 373():n784. PubMed ID: 34011512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time to include buprenorphine-naloxone combination in the WHO Model List of Essential Medicines.
    Balhara YP
    J Opioid Manag; 2013; 9(4):237. PubMed ID: 24380101
    [No Abstract]   [Full Text] [Related]  

  • 17. CE: Acute Pain Management for People with Opioid Use Disorder.
    Broglio K; Matzo M
    Am J Nurs; 2018 Oct; 118(10):30-38. PubMed ID: 30211703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders.
    McCann DJ
    Clin Pharmacol Ther; 2008 Apr; 83(4):627-30. PubMed ID: 18212797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary Care-Based Models for the Treatment of Opioid Use Disorder: A Scoping Review.
    Korthuis PT; McCarty D; Weimer M; Bougatsos C; Blazina I; Zakher B; Grusing S; Devine B; Chou R
    Ann Intern Med; 2017 Feb; 166(4):268-278. PubMed ID: 27919103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medication-Assisted Treatment Considerations for Women with Opiate Addiction Disorders.
    Jacobs AA; Cangiano M
    Prim Care; 2018 Dec; 45(4):731-742. PubMed ID: 30401353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.